(Q44237060)

English

Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives

scientific article published in December 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives (English)

1 reference

Europe PubMed Central

1 December 2017

1 reference

based on heuristic

inferred from title

Alessandro Tossi

3

1 reference

Europe PubMed Central

1 December 2017

Stanislav Miertuš

5

1 reference

Europe PubMed Central

1 December 2017

author name string

Anil C Nair

1

1 reference

Europe PubMed Central

1 December 2017

Irena Bonin

2

1 reference

Europe PubMed Central

1 December 2017

William J Wels

4

1 reference

Europe PubMed Central

1 December 2017

publication date

1 December 2002

1 reference

Europe PubMed Central

1 December 2017

Journal of Molecular Graphics & Modelling

1 reference

Europe PubMed Central

1 December 2017

21

1 reference

Europe PubMed Central

1 December 2017

3

1 reference

Europe PubMed Central

1 December 2017

171-179

1 reference

Europe PubMed Central

1 December 2017

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV protease: a novel chemotherapeutic target for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting HIV-1 protease: a test of drug-design methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of drug resistance to HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug resistance in viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Versatile and Stereoselective Synthesis of Diamino Diol Dipeptide Isosteres, Core Units of Pseudopeptide HIV Protease Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system.

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular properties that influence the oral bioavailability of drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1093-3263%2802%2900149-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1093-3263(02)00149-3

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44237060&oldid=2108833811"